130 related articles for article (PubMed ID: 25611185)
1. Long-lasting complete remission after therapy with temozolomide in two patients with macrocorticotropinoma causing Cushing's disease.
Bruno OD; Juárez-Allen L; Christiansen SB; Danilowicz K
Clin Endocrinol (Oxf); 2015 Jul; 83(1):143-5. PubMed ID: 25611185
[No Abstract] [Full Text] [Related]
2. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
Gilis-Januszewska A; Wilusz M; Pantofliński J; Turek-Jabrocka R; Sokołowski G; Sowa-Staszczak A; Kluczyński Ł; Pach D; Zieliński G; Hubalewska-Dydejczyk A
Endokrynol Pol; 2018; 69(3):306-312. PubMed ID: 29319131
[TBL] [Abstract][Full Text] [Related]
3. Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Mendola M; Passeri E; Ambrosi B; Corbetta S
J Clin Endocrinol Metab; 2014 Aug; 99(8):2623-4. PubMed ID: 24823463
[No Abstract] [Full Text] [Related]
4. Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment.
Kurowska M; Tarach JS; Malicka J; Zieliński G; Maksymowicz M; Denew P
Endokrynol Pol; 2016; 67(5):526-533. PubMed ID: 27828691
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
Curtò L; Torre ML; Ferraù F; Pitini V; Altavilla G; Granata F; Longo M; Hofland LJ; Trimarchi F; Cannavò S
ScientificWorldJournal; 2010 Nov; 10():2132-8. PubMed ID: 21057727
[TBL] [Abstract][Full Text] [Related]
6. Potential role for retinoic acid in patients with Cushing's disease.
Pecori Giraldi F; Ambrogio AG; Andrioli M; Sanguin F; Karamouzis I; Corsello SM; Scaroni C; Arvat E; Pontecorvi A; Cavagnini F
J Clin Endocrinol Metab; 2012 Oct; 97(10):3577-83. PubMed ID: 22851491
[TBL] [Abstract][Full Text] [Related]
7. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Zacharia BE; Gulati AP; Bruce JN; Carminucci AS; Wardlaw SL; Siegelin M; Remotti H; Lignelli A; Fine RL
Neurosurgery; 2014 Apr; 74(4):E447-55; discussion E455. PubMed ID: 24226425
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Campderá M; Palacios N; Aller J; Magallón R; Martín P; Saucedo G; Lilienfeld H; Estrada J
Pituitary; 2016 Apr; 19(2):158-66. PubMed ID: 26586560
[TBL] [Abstract][Full Text] [Related]
9. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging.
Prevedello DM; Pouratian N; Sherman J; Jane JA; Vance ML; Lopes MB; Laws ER
J Neurosurg; 2008 Oct; 109(4):751-9. PubMed ID: 18826366
[TBL] [Abstract][Full Text] [Related]
10. Relapsing, remitting hypercortisolism in Cushing's disease due to intratumoral hemorrhages in pituitary microadenoma.
Marko NF; Hamrahian AH; Hatipoglu B; Weil RJ
J Clin Neurosci; 2013 May; 20(5):753-6. PubMed ID: 23352667
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
Cannavo S; Messina E; Albani A; Ferrau F; Barresi V; Priola S; Esposito F; Angileri F
Endocrine; 2016 Jun; 52(3):481-7. PubMed ID: 25877016
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing's Disease.
Shen Y; Ji C; Jian X; Zhou J; Zhang Q; Qiao N; Zhang Y; Shou X; Zhou X; Ma Z
Front Endocrinol (Lausanne); 2020; 11():601984. PubMed ID: 33537004
[TBL] [Abstract][Full Text] [Related]
13. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and management of patients with Cushing's disease without pathological confirmation of tumor resection after transsphenoidal surgery.
Pouratian N; Prevedello DM; Jagannathan J; Lopes MB; Vance ML; Laws ER
J Clin Endocrinol Metab; 2007 Sep; 92(9):3383-8. PubMed ID: 17595252
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
16. Current status on histological classification in Cushing's disease.
Syro LV; Rotondo F; Cusimano MD; Di Ieva A; Horvath E; Restrepo LM; Wong M; Killinger DW; Smyth H; Kovacs K
Pituitary; 2015 Apr; 18(2):217-24. PubMed ID: 25501318
[TBL] [Abstract][Full Text] [Related]
17. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome.
De Tommasi C; Vance ML; Okonkwo DO; Diallo A; Laws ER
J Neurosurg; 2005 Nov; 103(5):825-30. PubMed ID: 16304985
[TBL] [Abstract][Full Text] [Related]
18. Pituitary-directed medical therapy in Cushing's disease.
Petersenn S; Fleseriu M
Pituitary; 2015 Apr; 18(2):238-44. PubMed ID: 25627118
[TBL] [Abstract][Full Text] [Related]
19. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
20. Pituitary corticotroph hyperplasia preceding adenoma in a patient with Nelson's syndrome.
Kovacs K; Horvath E; Coire C; Cusimano M; Smyth H; Scheithauer BW; Lloyd RV
Clin Neuropathol; 2006; 25(2):74-80. PubMed ID: 16550740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
